Merck & Co Inc
Change company Symbol lookup
Select an option...
MRK Merck & Co Inc
DIS Walt Disney Co
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc
AGS PlayAGS Inc
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Closing Price
$85.81
Day's Change
0.17 (0.20%)
Bid
--
Ask
--
B/A Size
--
Day's High
86.30
Day's Low
84.94
Volume
(Heavy Day)
Volume:
11,744,659

10-day average volume:
9,234,583
11,744,659

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, September 18, 2020
LYNPARZA(R) (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo

AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that LYNPARZA demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with...(BusinessWire)

LYNPARZA(R) (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive five-year follow-up data from the Phase 3 SOLO-1 trial which demonstrated a long-term progression-free survival (PFS) benefit of LYNPARZA...(BusinessWire)

September 17, 2020
CISO of MGM Resorts International Branden Newman Joins Intezer's Board of Advisors

Branden Newman is the latest cybersecurity industry leader to join Intezer's growing profile. The current CISO of MGM Resorts International and former Adidas CISO brings with him over 20 years of experience serving as Head of Global Information...(PR Newswire)

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020 Panelists Include Representatives from IAVI, Merck and Tonix Pharmaceuticals Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a...(Globe Newswire)

September 16, 2020
Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Baum Hedlund Aristei & Goldman filed a Gardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine. (PR Newswire)

Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that members of management will host a virtual investor event following the European Society for Medical Oncology (ESMO) Virtual Congress 2020 where they will...(BusinessWire)

Cardiovascular Drugs Market to Exhibit a CAGR of 3.8% and Reach USD 63.96 Billion by 2026; Increasing Prevalence of Cardiovascular Diseases to Augment Growth, says Fortune Business Insights

Global cardiovascular drugs market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth...(Globe Newswire)

September 15, 2020
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, executive vice president and chief marketing officer, is scheduled to participate in a virtual fireside chat at the Cantor Fitzgerald Virtual...(BusinessWire)

Volansi Raises $50 Million to Accelerate Middle-Mile Drone Delivery

New financing, led by Icon Ventures, will allow Volansi to rapidly scale in the US and global emerging markets Volansi, Inc., the leader in vertical take-off and landing (VTOL) middle-mile drone delivery services, today announced that it has closed...(PR Newswire)

September 14, 2020
Merck Manuals Offers Expert Advice on Recognizing and Preventing Dehydration

Dehydration is a serious condition that can require medical attention if not properly addressed. Dehydration is a deficiency of water in the body. When the body loses too much water, it can lead to dangerous symptoms including light-headedness...(PR Newswire)

Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Recruitment of Les Funtleyder as Director

Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands ("Tenzing") (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation ("Reviva") and a California-based clinical stage...(PR Newswire)

Monoclonal Antibody Therapy Market to Reach USD 350.10 Billion by 2027; Increasing Number of Regulatory Approvals Will Aid Growth, says Fortune Business Insights(TM)

The global monoclonal antibodies therapy market size is projected to reach USD 350.10 billion by the end of 2027. The increasing prevalence of severe diseases such as cancer will create several opportunities for the companies operating in the...(Globe Newswire)

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

--Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe --Seattle Genetics to Host Conference Call Today at 9:00 a.m. ET (BusinessWire)

September 10, 2020
AeroSafe Global Announces Closing of Growth Financing Round

AeroSafe Global (AeroSafe) announced today the closing of a $47.5 million round of growth financing with participation from new investors Merck Global Health Innovation Fund (GHI) and Escalate Capital, along with existing investors Peloton Equity...(BusinessWire)

Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate in...(BusinessWire)

September 09, 2020
Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck's Keytruda(R) in Phase 2 Studies

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patients have been dosed with...(BusinessWire)

Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial

--Application for V114 Licensure in Adults to Be Submitted by Year-End Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the...(BusinessWire)

September 08, 2020
Merck's Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally...(BusinessWire)

Biopharma Leaders Unite to Stand With Science

The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA)...(BusinessWire)

Biopharma Leaders Unite to Stand with Science

The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech SE (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA)...(Globe Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.